TOP TEN perturbations for 38387_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38387_at
Selected probe(set): 203565_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38387_at (203565_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.7102776Number of Samples:3 / 3
| Experimental | glioma study 17 (astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):2.479432Number of Samples:2 / 4
| Experimental | glioma study 17 ( small cell glioblastoma; unsorted) |
| Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.3797455Number of Samples:2 / 3
| Experimental | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). |
zalypsis study 1 / untreated MM1S cell sample
Relative Expression (log2-ratio):-2.12572Number of Samples:2 / 2
| Experimental | zalypsis study 1 |
| MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
| Control | untreated MM1S cell sample |
| MM1S multiple myeloma cells untreated. |
lung cancer study 1 (PDX; basaloid carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Relative Expression (log2-ratio):2.028535Number of Samples:3 / 4
| Experimental | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; adenosquamous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted). |
FoxO3 overexpr. study 1 / 4-hydroxytamoxifen study 1 (empty vector)
Relative Expression (log2-ratio):2.0134764Number of Samples:3 / 3
| Experimental | FoxO3 overexpr. study 1 |
| Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP-FoxO3.A3.ER vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of FoxO3 (forkhead box O3), treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:--- | |
| Control | 4-hydroxytamoxifen study 1 (empty vector) |
| Human umbilical vein endothelial cells (HUVECs) transfected with empty retroviral pBabe puro vector designed for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:--- |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)
Relative Expression (log2-ratio):-1.9720545Number of Samples:2 / 25
| Experimental | colorectal cancer study 43 (metastase; brain) |
| Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
| Control | colorectal cancer study 43 (metastase; liver) |
| Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.9549236Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
T-cell activation study 1 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):1.9328661Number of Samples:2 / 2
| Experimental | T-cell activation study 1 |
| CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day. | |
| Control | quiescent CD4+ T-cell sample |
| Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |
T-cell activation study 2 / quiescent CD4+ T-cell sample
Relative Expression (log2-ratio):1.8826027Number of Samples:2 / 2
| Experimental | T-cell activation study 2 |
| CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days.. | |
| Control | quiescent CD4+ T-cell sample |
| Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors. |